MX2022012986A - Pirfenidona para el tratamiento del coronavirus. - Google Patents

Pirfenidona para el tratamiento del coronavirus.

Info

Publication number
MX2022012986A
MX2022012986A MX2022012986A MX2022012986A MX2022012986A MX 2022012986 A MX2022012986 A MX 2022012986A MX 2022012986 A MX2022012986 A MX 2022012986A MX 2022012986 A MX2022012986 A MX 2022012986A MX 2022012986 A MX2022012986 A MX 2022012986A
Authority
MX
Mexico
Prior art keywords
virus
pirfenidone
subject
coronavirus
cov
Prior art date
Application number
MX2022012986A
Other languages
English (en)
Spanish (es)
Inventor
Estuardo Aguilar-Cordova
Laura Aguilar
Castro José Agustin Rogelio Magaña
Original Assignee
Excalibur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excalibur Pharmaceuticals Inc filed Critical Excalibur Pharmaceuticals Inc
Publication of MX2022012986A publication Critical patent/MX2022012986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
MX2022012986A 2020-04-14 2021-04-14 Pirfenidona para el tratamiento del coronavirus. MX2022012986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
MX2022012986A true MX2022012986A (es) 2023-03-21

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012986A MX2022012986A (es) 2020-04-14 2021-04-14 Pirfenidona para el tratamiento del coronavirus.

Country Status (14)

Country Link
US (1) US20230117397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135671A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521887A (cg-RX-API-DMAC7.html)
KR (1) KR20230038644A (cg-RX-API-DMAC7.html)
CN (1) CN115916162A (cg-RX-API-DMAC7.html)
AU (1) AU2021254765A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020821A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002843A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016155A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22087664A (cg-RX-API-DMAC7.html)
IL (1) IL297296A (cg-RX-API-DMAC7.html)
MX (1) MX2022012986A (cg-RX-API-DMAC7.html)
WO (1) WO2021211745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030103941A1 (en) * 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
JP7066321B2 (ja) * 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Also Published As

Publication number Publication date
CL2022002843A1 (es) 2023-09-01
CN115916162A (zh) 2023-04-04
EP4135671A1 (en) 2023-02-22
ECSP22087664A (es) 2022-12-30
BR112022020821A2 (pt) 2022-12-20
IL297296A (en) 2022-12-01
KR20230038644A (ko) 2023-03-21
EP4135671A4 (en) 2024-08-14
US20230117397A1 (en) 2023-04-20
WO2021211745A1 (en) 2021-10-21
CA3175526A1 (en) 2021-10-21
AU2021254765A1 (en) 2022-12-08
CO2022016155A2 (es) 2022-12-20
JP2023521887A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
BR112022020821A2 (pt) Pirfenidona para tratamento de coronavírus
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
Vitiello et al. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
Dang et al. Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response
MX2022014786A (es) Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN112778310A8 (zh) 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
Roustit et al. Chloroquine and hydroxychloroquine in the management of COVID-19: much kerfuffle but little evidence
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
UY27650A1 (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
Liu et al. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection
JP2023521887A5 (cg-RX-API-DMAC7.html)
BR112022017240A2 (pt) Cepas bacterianas e composições das mesmas para uso oral no tratamento de infecções virais do sistema respiratório
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
WO2021207399A1 (en) Hydrolysable tannins for use in mitigating acute respiratory distress syndrome
WO2008060695A3 (en) Antiviral inhibition of casein kinase ii
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
CN116421587A (zh) 双(苯基乙烯基)类化合物在制备冠状病毒3cl蛋白酶抑制剂中的应用
ZA202211004B (en) 3clpro-targeting phillyrin, derivative thereof, and use thereof against novel coronavirus
Zheng et al. Leflunomide: traditional immunosuppressant with concurrent antiviral effects
CY1115876T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο μιας τριαζολοβενζοδιαζεπινης και ενος εκλεκτικου αναστολεα της επαναπροσληψης σεροτονινης
WO2024086777A3 (en) Compounds and methods for treating diseases caused by viruses and bacteria
Naik et al. Therapeutic Strategies in the Management of COVID-19
Han et al. Efficacy of CP-COV03 (a niclosamide-based inorganic nanohybrid product) against severe fever with thrombocytopenia syndrome virus in an in vitro model